OHRI MANU (Chief Financial Officer) received a stock award from GT BIOPHARMA, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 8/15/2023ACC: 0001493152-23-029059
Officer· Chief Financial Officer
Since Feb 2022
+200K
Net shares
Net buyer
$57.4K
Total sold
0
Open market trades
0B · 0S
3
Total transactions
400K acquired · 200K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+200K
Price / share
$0.29
Trade value
$57.40K
% of position
New position
8/11/2023
0.00→200K
Common Stock
Direct
Shares
−200K
Price / share
$0.29
Trade value
$57.40K
% of position
New position
8/11/2023
200K→0.00
Common Stock
Indirect
Shares
+200K
Price / share
$0.29
Trade value
$57.40K
% of position
200.0%
8/11/2023
100K→300K
Total
Net shares
+200K
Net value
$57.40K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/11/2023 | A · Award | +200K | $0.29 | $57.40K | New position | 0.00 | 200K |
| Common Stock Direct | 8/11/2023 | J · J | −200K | $0.29 | $57.40K | New position | 200K | 0.00 |
| Common Stock Indirect | 8/11/2023 | J · J | +200K | $0.29 | $57.40K | 200.0% | 100K | 300K |
| Total | +200K | $57.40K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned50K
Total
50K indirect50K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 50K | Indirect |
| Total | 50K | 50K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported